25934-52-5

Usage

Uses

Used in Pharmaceutical Industry:
3-Cyclopropylmethoxy-4-hydroxybenzaldehyde is used as a reactant in the preparation of ethyl (alkoxy)(cyclopropylmethoxy)-4-hydroxy-3-quinolinecarboxylates. These quinolinecarboxylate derivatives are of interest in the pharmaceutical industry due to their potential as therapeutic agents, particularly in the development of new drugs targeting various diseases and conditions.
In the synthesis of these ethyl (alkoxy)(cyclopropylmethoxy)-4-hydroxy-3-quinolinecarboxylates, 3-cyclopropylmethoxy-4-hydroxybenzaldehyde serves as a key intermediate, contributing to the formation of the desired quinolinecarboxylate structure. The cyclopropylmethoxy group imparts unique properties to the final product, which may enhance its pharmacological activity, selectivity, and bioavailability.
Overall, 3-Cyclopropylmethoxy-4-hydroxybenzaldehyde plays a crucial role in the development of novel pharmaceutical compounds, particularly in the area of quinolinecarboxylate-based drugs, offering potential benefits in the treatment of various medical conditions.

Upstream product

• 1381886-14-1 4-(benzyloxy)-3-(cyclopropylmethoxy)benzaldehyde 
• 4049-39-2 4-benzyloxy-3-hydroxy-benzaldehyde 
• 2973-78-6 3-bromo-4-hydroxybenzylaldehyde 

Downstream Products

• 162401-62-9 3-(cyclopropylmethoxy)-4-(difluoromethoxy)-benzoic acid 
• 672883-68-0 3-(cyclopropylmethoxy)-4-(difluoromethoxy)benzoyl chloride 
• 151103-09-2 3-(cyclopropylmethoxy)-4-(difluoromethoxy)-benzaldehyde 

Relevant academic research and scientific papers

Novel 3-cyclopropylmethoxy-4-alkoxybenzamide PDE (phosphodiesterase) 4 inhibitors

The invention discloses novel 3-cyclopropylmethoxy-4-alkoxybenzamide PDE (phosphodiesterase) 4 inhibitors. The inhibitors are compounds represented in a general formula I or a general formula II, prodrugs thereof, pharmaceutically usable salts thereof or solvates thereof, wherein R is independent methyl (Me-) or difluoromethyl (CF2H-); R is independent H, Me or Et; R is independent H, MeO or Cl; CnH(2n+2) is alkyl, and N is larger than or equal to 2; a substance shown in the specification is a substituted benzene ring or pyridine ring; X is C or N; Y is C or N. The novel 3-cyclopropylmethoxy-4-alkoxybenzamide PDE 4 inhibitors have the advantages of high in-vitro enzyme inhibition activity, capability of selective application to PDE4 and good anti-inflammation effect and anti-depression effect.

PERFUME SYSTEMS

The present application relates to perfume raw materials, perfume delivery systems and consumer products comprising such perfume raw materials and/or such perfume delivery systems, as well as processes for making and using such perfume raw materials, perfume delivery systems and consumer products. Such perfume raw materials and compositions, including the delivery systems, disclosed herein expand the perfume communities' options as such perfume raw materials can provide variations on character and such compositions can provide desired odor profiles.